Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
National Centre for Infection in Cancer, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Expert Rev Anti Infect Ther. 2021 Jun;19(6):749-758. doi: 10.1080/14787210.2021.1855143. Epub 2020 Dec 31.
: Chimeric antigen receptor T-cell therapy (CAR-T cell therapy) is a novel immunotherapy with promising results in the treatment of relapsed or refractory B cell malignancies. Patients undergoing CAR-T cell therapy are at increased risk of infection due to prior immunosuppression, lymphodepleting chemotherapy, treatment of unique toxicities with tocilizumab and/or steroids, on-target effects of hypogammaglobulinaemia, and prolonged cytopenias.: A narrative review of infections (PubMed, August 2020) occurring in patients undergoing CAR-T cell therapy is described, and the evidence for infection prevention strategies is presented.: The rapid adoption of CAR-T cell therapy into clinical practice presents many challenges for the diagnosis, management, and prevention of infection. Ongoing surveillance of the spectrum of infectious complications and effectiveness of prophylaxis is required to support safe and effective patient care.
嵌合抗原受体 T 细胞疗法（CAR-T 细胞疗法）是一种新型免疫疗法，在治疗复发或难治性 B 细胞恶性肿瘤方面具有广阔的前景。由于先前的免疫抑制、淋巴清除化疗、托珠单抗和/或类固醇治疗独特的毒性、低丙种球蛋白血症的靶向作用以及长期细胞减少，接受 CAR-T 细胞疗法的患者感染风险增加。本文对接受 CAR-T 细胞疗法的患者发生的感染（2020 年 8 月 PubMed）进行了叙述性综述，并提出了感染预防策略的证据。CAR-T 细胞疗法在临床实践中的快速采用给感染的诊断、管理和预防带来了许多挑战。需要对感染并发症的范围和预防效果进行持续监测，以支持安全有效的患者护理。
